Embattled Mylan Boosts EpiPen Patient Programs, Doesn't Budge on Price | NBC4 Washington
National & International News
The day’s top national and international news

Embattled Mylan Boosts EpiPen Patient Programs, Doesn't Budge on Price

Mylan has hiked prices for EpiPen as frequently as three times a year over the past nine years



    You’ve probably heard about the cost of the life-saving Epipen skyrocketing. Now the drug maker is promising discounts, but they’re not the only manufacturer in town. There’s also a cheaper alternative. Roseanne Colletti reports. (Published Thursday, Aug. 25, 2016)

    Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade. 

    But the drugmaker didn't budge on its price hikes Thursday, which have drawn ire both in Congress and from families that have had to shell out increasingly large sums for the potentially life-saving treatment. 

    That means the insurers and employers that pay the bulk of the EpiPen cost for many patients will continue to do so, contributing to higher health insurance costs. 

    "That's just going to come out in the premiums," said Sabrina Corlette, a research professor at the Georgetown University's Health Policy Institute. "Everybody suffers, except the Mylan investors." 

    Yoga Pants Parade Protests Op-Ed in Rhode Island

    [NATL] Yoga Pants Parade Protests Op-Ed in Rhode Island
    Hundreds of people took to the streets in Barrington, Rhode Island this weekend to protest an op-ed written in the local newspaper that many found offensive. The letter, written by Alan Sorrentino, critiques older women who wear yoga pants in public, saying the clothing does not compliment a woman over 20 years-old. "This is way more than yoga pants. It is women fed up with the policing of our wardrobes," said parade organizer, Jamie Burke. Sorrentino claims that his op-ed was just a joke but many are calling his comments sexist. (Published Tuesday, Oct. 25, 2016)

    Mylan joins a growing list of drugmakers, Turing Pharmaceuticals and Valeant Pharmaceuticals International Inc. among them, that have been called out after mammoth price hikes for the drugs they sell, with little or no innovation. 

    Turing's former CEO Martin Shkreli became the poster child of pharmaceutical-industry greed last fall for hiking the price of a life-saving drug, Daraprim, by more than 5,000 percent. 

    He has applauded Mylan's actions. 

    The average price of a two-dose EpiPen package climbed to about $608 earlier this year, up more than 500 percent from around $94 nine years ago, according to the Elsevier Clinical Solutions' Gold Standard Drug Database. 

    Adorable Twin Panda Cubs Feast on Special Cake

    [NATL-DFW] Cute Pandas Celebrate 100 Days
    Twin panda cubs in a zoo in southwest China have celebrated their first 100 days of life. They feasted on a specially made cake at a party of visitors. (Published Tuesday, Oct. 25, 2016)

    Mylan CEO Heather Bresch told CNBC Thursday that lowering the price was not an option. 

    "Had we reduced the list price, I couldn't ensure that everyone who needs an EpiPen gets one," she said. 

    EpiPens are used in emergencies to treat severe allergies that can lead to anaphylactic shock. Roughly 40 million Americans have severe allergies to spider bites, bee stings and foods like nuts, eggs and shellfish. 

    Democratic presidential candidate Hillary Clinton and members of Congress from both parties have quickly ramped up criticism of the price Mylan charges for the medicine. 

    Clinton said Wednesday that pharmaceutical and biotech industries can fuel American innovation, and combat debilitating diseases. But she added that "it's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them." 

    Bresch said Thursday that Mylan gets $274 for a two-dose EpiPen package. The rest of the $608 price goes to entities that stand between the drugmaker and the patient, like insurers, pharmacy benefits managers, wholesalers and drugstores. 

    "This isn't an EpiPen issue," she said. "This isn't a Mylan issue. This is a health care issue." 

    However, it is Mylan that is increasing the price of the drug and the company stuck by those price hikes Thursday. 

    Infants, Parents Should Share Room: New Guidelines

    [NATL] Infants, Parents Should Share Room: New Guidelines for Infant Sleep Safety
    The American Academy of Pediatrics has released updated guidelines for new parents on infant sleep safety. Experts say room sharing could reduce the risk of sudden infant death syndrome (SIDS) by half and recommend babies sleep in a crib or bassinet in the parent's bedroom for at least the first six months and up to age 1. (Published Monday, Oct. 24, 2016)

    That stance brought a wave of new money from investors who drove Mylan's shares up more than 2 percent in morning trading, while major U.S. indexes slipped. 

    Last year, more than 3.6 million U.S. prescriptions for two-packs of EpiPens were filled, according to data firm IMS Health. That brought in sales of nearly $1.7 billion for Mylan. 

    Mylan said Thursday that it was doubling the eligibility for its patient assistance program to people with incomes four times higher than the federal poverty level. It said that means a family of four making up to $97,200 would pay nothing out of pocket for the treatment. It also noted that its $300 savings card would cut the bill in half for patients who would otherwise have to pay full price for the EpiPen. 

    Patients also will be able to order the injected medicine directly from the company, to help lower costs. 

    Baby Lemur Makes London Zoo Debut

    [NATL-DFW] Baby Lemur Makes London Zoo Debut

    London Zoo is welcoming the first ever baby aye-aye lemur just in time for Halloween.

    The creepy-looking creature was actually born on July 1 but has only emerged from its secluded nesting box for the first time this week.

    The species of lemur (formally known as Daubentonia madagascariensis) are unique in that they have an unusually large middle finger and are associated with doom in their native Madagascar. Natives there believe that if an aye-aye points its long finger at you, death is not far away.

    Zookeepers expressed their excitement at the birth although they only saw the baby recently as it has been hiding in its nest box.

    (Published Monday, Oct. 24, 2016)

    These measures could provide significant help for people with no coverage facing the full bill. But they might have more limited value to a patient whose insurer will cover most of the bill anyway and whose future premium could be affected by the drug's price. 

    Customers of Express Scripts Holding Co., the nation's largest pharmacy benefits manager, pay about $73.50 out of pocket for an EpiPen prescription, spokesman Brian Henry said. He noted that price has stayed relatively stable the past couple years. 

    Sen. Richard Blumenthal, D-Connecticut, dismissed the actions Mylan detailed Thursday as a baby step. 

    "This step seems like a PR fix more than a real remedy, masking an exorbitant and callous price hike," the senator said in a statement.

    Police Chase Turns Into Shootout in California

    [NATL] Police Chase Turns Into Shootout in California
    A police pursuit turned into a shootout early Sunday morning in California when a Madera police officer with a civilian ride-along in the car tried to pull over a white Mazda SUV. The SUV driver refused to stop and instead shot at the cop car, hitting the windshield. The officer was not hurt and the civilian had minor scratches from broken glass. Suspects are still at-large, according to police. (Published Monday, Oct. 24, 2016)